Curia Global is laying off 81 employees as part of its plan to shut down its drug product development and manufacturing facility in Burlington, Massachusetts, according to a Worker Adjustment and Retraining Notification. More: Curia's Mass. plant closure to eliminate
read moreGSK, through its oncology subsidiary Tesaro, is handing over $20 million upfront to Alteogen for global rights to the Korean biotech’s novel hyaluronidase ALT-B4. Tesaro plans to use ALT-B4 to develop and potentially market a subcutaneous form of the ascendant
read moreTakeda is executing another round of layoffs, cutting 243 roles in the United States. The company is preparing for an upcoming patent loss on depression drug Trintellix. More: Takeda's neuroscience field force hit with layoffs as key patent loss looms
read more
The firm already has a number of offices across the UK and Europe More: Venner Shipley announces opening of new Bristol office Source: News
read more
The collaboration will help to advance a pipeline of antibody candidates More: AAX Biotech and Vascurie announce new neuro-oncology collaboration Source: News
read moreRoche is more than doubling its total commitment to a future facility for its Genentech unit to approximately $2 billion. The plant, being built in Holly Springs, North Carolina, will be used to crank out next-generation drugs for metabolic conditions
read more© 1994 - 2026 B.M. Pharmaceuticals